Press Releases

Media Focus

Embracing a quality mindset for successful end-to-end CDMO operations


A quality mindset is the foundation for CDMOs to bring innovative solutions in time for clients. Working with people ingrained in such a mindset can support clients to appropriately leverage cutting-edge technologies, advanced platforms and facilities, and scalable bioreactors to complete true end-to-end drug development and manufacturing. 


Three of our industry veterans - Daniel Buckley of drug development, Soyeon Ahn of drug substance manufacturing, and Sungjin Park of drug product manufacturing - provide their real-life thought leadership on how working with a quality-minded CDMO leads to agile problem-solving of biopharmaceutical challenges. 


Read this European Biopharmaceutical Review article to learn how CDMOs can cultivate a culture of quality. 


Read more (page 13)



A quality mindset is the foundation for CDMOs to bring innovative solutions in time for clients. Working with people ingrained in such a mindset can support clients to appropriately leverage cutting-edge technologies, advanced platforms and facilities, and scalable bioreactors to complete true end-to-end drug development and manufacturing. 


Three of our industry veterans - Daniel Buckley of drug development, Soyeon Ahn of drug substance manufacturing, and Sungjin Park of drug product manufacturing - provide their real-life thought leadership on how working with a quality-minded CDMO leads to agile problem-solving of biopharmaceutical challenges. 


Read this European Biopharmaceutical Review article to learn how CDMOs can cultivate a culture of quality. 


Read more (page 13)

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION